Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis
European Journal of Haematology · 2026-07 · 117 (1) · 88-99
DOI: 10.1111/ejh.70175 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Haematology, online erschienen am 25.03.2026. Verfasst von Marcos Niedziewski Goularte und 2 weiteren Autor:innen. Beteiligte Einrichtung: Universidade da Região de Joinville-UNIVILLE, SC, Brazil. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To evaluate the efficacy and safety of venetoclax combined with intensive chemotherapy regimens in patients with relapsed or refractory acute myeloid leukemia (R/R AML) through a systematic review and single‐arm meta‐analysis.
Methods
A systematic search of PubMed, Embase, and Cochrane CENTRAL was conducted from inception to January 2025. Non‐randomized studies enrolling R/R AML patients treated with venetoclax plus intensive chemotherapy were included. Pooled rates of complete remission (CR), composite complete remission (CRc), overall response rate (ORR), and adverse events were estimated using random‐effects models. Heterogeneity was assessed with I 2 statistics, and sensitivity and subgroup analyses were performed according to chemotherapy regimen.
Results
Six retrospective studies comprising 235 patients were included. The pooled CR rate was 27.0% (95% CI, 9.18–57.50; I 2 = 84.6%), CRc rate was 51.45% (95% CI, 36.15–66.76; I 2 = 83.5%), and ORR was 63.79% (95% CI, 49.67–77.92; I 2 = 82.0%). Febrile neutropenia occurred in 71.38% and pneumonia in 23.6% of patients.
Conclusions
Venetoclax combined with intensive chemotherapy demonstrates meaningful antileukemic activity in R/R AML, with an expected toxicity profile. Prospective trials are warranted to define its role relative to standard salvage therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universidade da Região de Joinville-UNIVILLE, SC, Brazil.
- Departamento de Hematologia e Oncologia, Hospital Municipal São José, SC, Brazil.
ORCID-Profile: Marcos Niedziewski Goularte, Mariany Hatori Miyamoto, Marcelo Pitombeira de Lacerda
Zitieren
APA
Goularte, M. N., Miyamoto, M. H., & de Lacerda, M. P. (2026). Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis. European Journal of Haematology, 117(1), 88-99. https://doi.org/10.1111/ejh.70175
Vancouver
Goularte MN, Miyamoto MH, de Lacerda MP. Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis. European Journal of Haematology. 2026;117(1):88-99. doi:10.1111/ejh.70175
BibTeX
@article{Goularte2026,
author = {Goularte, Marcos Niedziewski and Miyamoto, Mariany Hatori and de Lacerda, Marcelo Pitombeira},
title = {Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {88--99},
doi = {10.1111/ejh.70175}
}
EUVIMED